Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2b, randomized, multicenter, active-controlled, open-label study to evaluate the efficacy and safety of Albuferon (recombinant human albumin-interferon alfa fusion protein) in combination with ribavirin in interferon alfa naive subjects with chronic hepatitis C genotype 1.

Next Previous
X
Search
Trial Profile

A phase 2b, randomized, multicenter, active-controlled, open-label study to evaluate the efficacy and safety of Albuferon (recombinant human albumin-interferon alfa fusion protein) in combination with ribavirin in interferon alfa naive subjects with chronic hepatitis C genotype 1.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Albinterferon alfa 2B (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Human Genome Sciences

    • Most Recent Events

    • 27 Apr 2011 Actual end date (1 May 2007) added as reported by ClinicalTrials.gov.
    • 22 May 2008 Results were reported at the Digestive Disease Week 2008.
    • 06 Nov 2007 Quality-of-life results at 12 and 24 weeks presented at AASLD 2007.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top